Yemen
Tuberculosis profile
Population  2012 24 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.3 (0.6–2.4) 5.6 (2.5–9.9)
Mortality (HIV+TB only) 0.029 (0.024–0.056) 0.12 (0.1–0.23)
Prevalence  (includes HIV+TB) 17 (7.1–30) 70 (30–127)
Incidence  (includes HIV+TB) 12 (9.6–14) 49 (40–58)
Incidence (HIV+TB only) 0.16 (0.098–0.23) 0.65 (0.41–0.95)
Case detection, all forms (%) 85 (71–100)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 3 321 (35) Relapse 252 (75)
Smear-negative 2 334 (24) Treatment after failure 29 (9)
Smear-unknown / not done 474 (5) Treatment after default 42 (13)
Extrapulmonary 3 486 (36) Other 12 (4)
Other 0 (0)      
Total new 9 615   Total retreatment 335  
           
Other (history unknown)          
Total new and relapse 9 867   Total cases notified 9 950  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.2 1.0 0.8
Age < 15 105 473 396
Laboratories 2012
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 0.8
Drug susceptibility testing (per 5 million population) 0.4
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 88   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 89  
Retreatment 67  
TB/HIV 2012 Number (%)
TB patients with known HIV status 612 (6)
HIV-positive TB patients 26 (4)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 16 (62)
HIV-positive people screened for TB 1 339  
HIV-positive people provided with IPT 0  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.5–3) 15 (8.1–22)
MDR-TB cases among notified pulmonary
TB cases
110 (31–180) 49 (27–73)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 183 (6%) 17 (5%) 200
Laboratory-confirmed MDR-TB cases 5 3 8
Patients started on MDR-TB treatment     0
Financing TB control 2013
National TB programme budget (US$ millions) 9.5
% Funded domestically 6%
% Funded internationally 71%
% Unfunded 23%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-17 Data: www.who.int/tb/data